Table 2.
Proportion of HIV viral suppression by socio-demographic and clinical characteristics of the CALHIV on DTG-based ART (N = 63,453)
| Variables | Viral Load | P-value | ||
|---|---|---|---|---|
| Unsuppressed n (%) 5,306 (8.36%) |
Suppressed (< 1000 copies/ml) | |||
|
n (%) 58,147 (91.64%) |
95% CI 91.42,91.85 |
|||
| Sex | ||||
| Male | 2,433 (8.90) | 24,912 (91.10) | 90.76,91.43 | < 0.001 |
| Female | 2,873 (7.96) | 33,235 (92.04) | 91.76,92.32 | |
| Age group (years) | ||||
| 1–4 | 1,684 (7.71) | 20,168 (92.29) | 91.93,92.64 | < 0.001 |
| 5–9 | 1,810 (9.05) | 18,199 (90.95) | 90.55,91.34 | |
| 10–14 | 1,123 (9.59) | 10,584 (90.41) | 89.86,90.93 | |
| 15–19 | 689 (6.97) | 9,196 (93.03) | 92.51,93.52 | |
| WHO staging | ||||
| Stage I | 2,015 (7.74) | 24,011 (92.26) | 91.93,92.58 | < 0.001 |
| Stage II | 1,585 (8.46) | 17,156 (91.54) | 91.14,91.93 | |
| Stage III | 1,449 (8.99) | 14,663 (91.01) | 90.56,91.44 | |
| Stage IV | 254 (9.90) | 2,311 (90.10) | 88.88,91.20 | |
| CD4 (cells/mm3) | ||||
| < 200 | 298 (9.61) | 2,803 (90.39) | 89.30,91.38 | 0.008 |
| 200–349 | 175 (9.19) | 1,730 (90.81) | 89.43,92.03 | |
| >=350 | 2,487 (8.16) | 27,985 (91.84) | 91.53,92.03 | |
| BMI (Kg/M2) | ||||
| Underweight | 1,610 (8.71) | 16,868 (91.29) | 90.87,91.69 | 0.512 |
| Normal | 262 (7.91) | 3,050 (92.09) | 91.12,92.96 | |
| Overweight | 44 (8.63) | 466 (91.37) | 88.60,93.52 | |
| Obesity | 119 (8.58) | 1,268 (91.42) | 89.83,92.78 | |
| Prior DTG status | ||||
| Experienced suppressed | 1,975 (5.72) | 32,582 (94.28) | 94.04,94.52 | < 0.001 |
| Experienced unsuppressed | 1,976 (15.15) | 11,065 (84.85) | 84.22,85.45 | |
| Naive | 471 (6.79) | 6,462 (93.21) | 92.59,93.78 | |
| Duration on ART | ||||
| 24 months or less | 724 (7.28) | 9,217 (92.72) | 92.19,93.21 | < 0.001 |
| > 24 months | 4,582 (8.56) | 48,930 (91.44) | 91.20,91.67 | |
| Current DTG regimen | ||||
| Other DTG regimen | 109 (7.31) | 1,383 (92.69) | 91.26,93.81 | 0.382 |
| TDF + 3TC + DTG (TLD) | 389 (6.67) | 5,445 (93.33) | 92.66,93.94 | |
| Ever received MMS | ||||
| No | 1,785 (23.88) | 5,691 (76.12) | 75.14,77.08 | < 0.001 |
| Yes | 3,521 (6.29) | 52,456 (93.71) | 93.51,93.91 | |
| Child exposed to PMTCT | ||||
| No | 4,896 (8.41) | 53,321 (91.59) | 91.36,91.81 | 0.147 |
| Yes | 410 (7.83) | 4,826 (92.17) | 91.41,92.87 | |
| History of TB treatment | ||||
| No | 4,749 (8.25) | 952,843 (91.75) | 91.53,91.98 | 0.001 |
| Yes | 557 (9.50) | 5,304 (90.50) | 89.72,91.22 | |
| Malnutrition status | ||||
| No malnutrition | 4,671 (8.40) | 50,930 (91.60) | 91.37,91.83 | < 0.001 |
| Mild & moderate | 49 (10.89) | 401 (89.11) | 85.88,91.68 | |
| Severe | 10 (31.25) | 22 (68.75) | 50.72,82.46 | |
| Retention in care | ||||
| Retained | 5,183 (8.22) | 57,864 (91.78) | 91.56,91.99 | < 0.001 |
| Not retained | 123 (30.30) | 283 (69.70) | 65.05,73.99 | |
| Facility type | ||||
| Dispensary | 1,365 (8.81) | 14,129 (91.19) | 90.73,91.63 | 0.021 |
| Health centre | 1,751 (8.47) | 18,914 (91.53) | 91.14,91.90 | |
| Hospital | 2,172 (8.05) | 24,805 (91.95) | 91.62,92.27 | |
| Facility ownership | ||||
| Private/FBO | 1,227 (8.14) | 13,839 (91.86) | 91.41,92.28 | 0.240 |
| Public | 4,061 (8.45) | 44,009 (91.55) | 91.30,91.79 | |
| Zone | ||||
| Central zone | 502 (7.71) | 6,008 (92.29) | 91.62,92.91 | < 0.001 |
| Coastal zone | 1,352 (10.09) | 12,048 (89.91) | 89.39,90.41 | |
| Lake zone | 1,023 (5.96) | 16,129 (94.04) | 93.67,94.38 | |
| Northern zone | 657 (8.72) | 6,879 (91.28) | 90.62,91.90 | |
| Southern highland | 1,618 (9.57) | 15,289 (90.43) | 89.98,90.86 | |
| Western zone | 136 (8.34) | 1,495 (91.66) | 90.22,92.91 | |
Key: Data are presented as n (row%)
CI confidence Interval; n frequency; %, percentage; DTG dolutegravir; TDF tenofovir; 3TC lamivudine; ABC abacavir; AZT azidothymidine (Zidovudine); MMS multi-month subscription; FBO faith-based organizations; ART antiretroviral therapy
*Chi-squared P-value